We analyzed the serum levels of sRANKL, periostin, and osteopontin in NDMM patients depending on the clinical stage and grade of MBD and their variations in the course of therapy to evaluate their potential as additional biomarkers for the assessment of MBD. This evidence concerns the gene POSTN and Marchiafava-Bignami disease.